Joshua R. Rhein - Infectious Diseases

Author Information

Joshua Rhein is a prominent researcher affiliated with the Infectious Diseases Institute at Makerere University in Kampala, Uganda, and the University of Minnesota in Minneapolis, MN, USA. His work primarily focuses on infectious diseases, with a particular emphasis on HIV-related conditions and opportunistic infections such as cryptococcal meningitis and pulmonary aspergillosis. His research contributions have significant implications for global health, especially in regions heavily burdened by infectious diseases.

Research Contributions

Joshua Rhein has made substantial contributions to the field of infectious diseases. His research includes studies on the treatment and management of cryptococcal meningitis, a severe fungal infection commonly associated with HIV. Notably, he has been involved in evaluating novel treatments like single-dose liposomal amphotericin B. Additionally, his work on the immunological responses to SARS-CoV-2 and the effects of sertraline on depression in HIV-related cryptococcal meningitis survivors highlights his diverse research interests. His studies are crucial in developing effective screening programs and treatment guidelines for infectious diseases.

Aliases

Joshua Rhein is also known by the aliases Josh Rhein and Joshua R. Rhein in various publications and academic circles.

Publication and Citation Metrics

Metrics	Values
Total Citation Count	3488
h-index	28
Total Paper Count	132

Publications:

Chronic pulmonary aspergillosis in patients with active pulmonary tuberculosis with persisting symptoms in Uganda.

DOI: 10.1111/myc.13444

Year: 2022

Convergent epitope specificities, V gene usage and public clones elicited by primary exposure to SARS-CoV-2 variants

DOI: 10.1101/2022.03.28.486152

Year: 2022

High Burden of Cryptococcal Meningitis Among Antiretroviral Therapy–Experienced Human Immunodeficiency Virus–Infected Patients in Northern Uganda in the Era of “Test and Treat”: Implications for Cryptococcal Screening Programs

DOI: 10.1093/ofid/ofac004

Year: 2022

Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.

DOI: 10.1056/NEJMoa2111904

Year: 2022

ATI-2307 Exhibits Equivalent Antifungal Activity in Cryptococcus neoformans Clinical Isolates With High and Low Fluconazole IC50

DOI: 10.3389/fcimb.2021.695240

Year: 2021

The effect of sertraline on depression and associations with persistent depression in survivors of HIV-related cryptococcal meningitis

DOI: 10.12688/WELLCOMEOPENRES.16363.1

Year: 2021

High-affinity memory B cells induced by SARS-CoV-2 infection produce more plasmablasts and atypical memory B cells than those primed by mRNA vaccines

DOI: 10.1016/j.celrep.2021.109823

Year: 2021

Implementation of an Anticoagulation Practice Guideline for COVID-19 via a Clinical Decision Support System in a Large Academic Health System and Its Evaluation: Observational Study (Preprint)

DOI: 10.2196/preprints.30743

Year: 2021

A Descriptive Analysis of Dried Blood Spot Adherence Testing Among Ugandans with HIV Presenting with Cryptococcal Meningitis.

DOI: 10.1089/AID.2020.0202

Year: 2021

Evaluation of the Diagnostic Performance of a Semiquantitative Cryptococcal Antigen Point-of-Care Assay among HIV-Infected Persons with Cryptococcal Meningitis

DOI: 10.1128/JCM.00860-21

Year: 2021

What are the Limitations of Serological Tests?

How Long Does It Take to Get Results?

How Does the Innate Immune System Recognize Pathogens?

What is Plasmodium?

What are the Implications of Colonization in Healthcare Settings?

How is Dengue Diagnosed?

What are Antiparasitics?

How is Yellow Fever Diagnosed?

What Are the Challenges in Targeting the Apicoplast?

How Does Aspirin Work?

Partnered Content Networks

Relevant Topics